ArticleJournal of the American Chemical Society2012
Silica microparticles as a solid support for gadolinium phosphonate magnetic resonance imaging contrast agents.
Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Preparation of polydentate phosphonate-functionalized adsorbent for selective extraction of rare earth ions in harsh acidic solution.Mikrochimica acta · 2025Article
- Effect of different silica coatings on the toxicity of upconversion nanoparticles on RAW 264.7 macrophage cells.Beilstein journal of nanotechnology · 2021Article
- Linear PVA-DTPA-Gd conjugate for magnetic resonance imaging.RSC advances · 2019Article
- A Novel Gd-DTPA-conjugated Poly(L-γ-glutamyl-glutamine)-paclitaxel Polymeric Delivery System for Tumor Theranostics.Scientific reports · 2017Article
- Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.Acta biomaterialia · 2016Article
- Biodegradable polysilsesquioxane nanoparticles as efficient contrast agents for magnetic resonance imaging.Small (Weinheim an der Bergstrasse, Germany) · 2013Article
- Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agents.International journal of molecular sciences · 2013Review
- Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents.Journal of materials chemistry. B · 2013Article
- Porphyrin-substituted H-NOX proteins as high-relaxivity MRI contrast agents.Inorganic chemistry · 2013Article
- Mn₃[Co(CN)₆]₂@SiO₂ core-shell nanocubes: novel bimodal contrast agents for MRI and optical imaging.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Particle-based magnetic resonance imaging (MRI) contrast agents have been the focus of recent studies, primarily due to the possibility of preparing multimodal particles capable of simultaneously targeting, imaging, and treating specific biological tissues in vivo. In addition, particle-based MRI contrast agents often have greater sensitivity than commercially available, soluble agents due to decreased molecular tumbling rates following surface immobilization, leading to increased relaxivities. Mesoporous silica particles are particularly attractive substrates due to their large internal surface areas. In this study, we immobilized a unique phosphonate-containing ligand onto mesoporous silica particles with a range of pore diameters, pore volumes, and surface areas, and Gd(III) ions were then chelated to the particles. Per-Gd(III) ionic relaxivities ranged from ∼2 to 10 mM(-1) s(-1) (37 °C, 60 MHz), compared to 3.0-3.5 mM(-1) s(-1) for commercial agents. The large surface areas allowed many Gd(III) ions to be chelated, leading to per-particle relaxivities of 3.3 × 10(7) mM(-1) s(-1), which is the largest value measured for a biologically suitable particle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.